



Edgar Filing: IMMUCCELL CORP /DE/ - Form 8-K

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



**Item 8.01 Other Events.**

On December 11, 2018, ImmuCell announced that it has received USDA licensure of **Dual-Force™ First Defense® Dual-Force™** in a single-dose oral syringe provides guaranteed levels of *E. coli* and coronavirus antibodies to prevent scours in newborn calves.

Additional information is provided in today's press release that is attached as Exhibit 99.1 to this Form 8-K.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

**Exhibit No. Description**

99.1 Press Release of ImmuCell Corporation, dated December 11, 2018.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**IMMUCELL CORPORATION**

Date: December 11, 2018 By: /s/ Michael F. Brigham  
Michael F. Brigham  
President and Chief Executive Officer

**EXHIBIT INDEX**

**Exhibit No. Description**

99.1 Press Release of ImmuCell Corporation, dated December 11, 2018.